Orthocell starts US sales of Remplir™ скачать в хорошем качестве

Orthocell starts US sales of Remplir™

Orthocell Ltd CEO Paul Anderson talked with Proactive about the company’s first commercial sales in the US of its flagship nerve repair product, Remplir™. This development marks a significant milestone for Orthocell, following the first surgical use of Remplir™ in the US back in June. According to Anderson, the company’s ability to secure sales just three months after FDA clearance reflects strong preparation and market readiness. “We've been working diligently over the last two years in preparation for this day,” Anderson said, highlighting efforts including infrastructure setup, collaborations with key opinion leaders, and distributor arrangements. Anderson described the achievement as “a really exciting jump shot,” emphasising that it signals the start of the company’s broader commercialisation strategy in the US. He also noted that the company’s recently reported quarterly and annual revenues – AU$2.73 million and AU$9.20 million respectively – did not yet include any US revenue, suggesting further potential upside. Orthocell now plans to maintain a laser focus on building its US presence and turning clinical collaborations into repeat commercial activity. Visit Proactive’s YouTube channel for more company updates. Don’t forget to like this video, subscribe to our channel, and enable notifications so you never miss a future update. #Orthocell #Remplir #NerveRepair #USHealthcare #MedicalDevices #FDAApproval #Neurosurgery #PaulAnderson #OrthocellUpdate #ProactiveInvestors